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ABSTRACT: The increased resistance of hypoxic cells to all forms of cancer therapy presents a major barrier to the successful
treatment of most solid tumors. Inhibition of the essential kinase Checkpoint kinase 1 (Chk1) has been described as a promising
cancer therapy for tumors with high levels of hypoxia-induced replication stress. However, as inhibition of Chk1 aﬀects normal
replication and induces DNA damage, these agents also have the potential to induce genomic instability and contribute to
tumorigenesis. To overcome this problem, we have developed a bioreductive prodrug, which functions as a Chk1/Aurora A
inhibitor speciﬁcally in hypoxic conditions. To achieve this activity, a key functionality on the Chk1 inhibitor (CH-01) is masked
by a bioreductive group, rendering the compound inactive as a Chk1/Aurora A inhibitor. Reduction of the bioreductive group
nitro moiety, under hypoxic conditions, reveals an electron-donating substituent that leads to fragmentation of the molecule,
aﬀording the active inhibitor. Most importantly, we show a signiﬁcant loss of viability in cancer cell lines exposed to hypoxia in
the presence of CH-01. This novel approach targets the most aggressive and therapy-resistant tumor fraction while protecting
normal tissue from therapy-induced genomic instability.
I t is clear that the identiﬁcation and exploitation of thediﬀerences between cancer and normal cells is essential for
the design of eﬀective therapeutics. The replicative stress
response (RSR), which is characterized by Ataxia telangiectasia
mutated rad3 related kinase-Checkpoint kinase 1 (ATR-Chk1)
signaling, is elevated in numerous cancer cell types.1 Targeting
ATR/Chk1 has been proposed to sensitize cancer cells to DNA
damage and to be particularly eﬀective in those that have lost
p53-mediated control of the G1 checkpoint.
2 Recently, targeting
the RSR through inhibition of the ATR-Chk1 pathway was
proposed as an eﬀective means of treating tumors with high
levels of oncogene-mediated replication stress.3,4 For example,
tumors with elevated MYC levels have been shown to be
sensitive to ATR/Chk1 inhibition.3,5−8 Both ATR and Chk1
inhibitors have been developed, although ATR inhibition has
yet to be evaluated in the clinic.9−14 Clinical studies using Chk1
inhibitors in combination with standard DNA damaging
chemotherapeutics have shown some success in combination
with, for example, gemcitabine, irinotecan, and paclitaxel.15,16
Recently, studies demonstrating that cancer cells with high
levels of oncogene-mediated replication stress or inherent DNA
damage show increased sensitivity to Chk1 inhibition have
raised the possibility of using Chk1 inhibitors as single agents.7
The enthusiasm for inhibiting kinases with roles in the cell cycle
is somewhat tempered due to their roles in normal,
unperturbed, replication.17 It cannot be forgotten, for example,
that Chk1 is an essential gene, the loss of which leads to
embryonic lethality and which perhaps more signiﬁcantly has
been found to be altered in human cancers.18 Indeed, a recent
study demonstrated that while signiﬁcant suppression of ATR
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activity led to loss of cell viability, ATR-haploinsuﬃciency
promoted tumorigenesis.4
In addition to tolerating high levels of oncogene-mediated
replication stress, tumors exist and thrive in conditions of low
oxygen concentration (hypoxia). The degree of tumor hypoxia
correlates well with resistance to therapy including radio/
chemotherapy and surgery as well as an increased likelihood of
metastasis.19,20 In conditions of severe hypoxia (<0.1% O2) a
unique DNA damage response (DDR) occurs, which is
characterized by both ATR and Ataxia telangiectasia mutated
kinase (ATM) activity in the absence of detectable DNA
damage.21,22 In response to these conditions the levels of
nucleotides rapidly fall, and this correlates with a complete
replication arrest. The RSR initiated in severe hypoxia includes
Chk1, and loss/inhibition of Chk1 has been demonstrated to
sensitize cells to hypoxia/reoxygenation.23
An elegant approach to exploiting the low levels of
oxygenation in tumors is through the use of agents that are
activated by these conditions, commonly known as bioreductive
prodrugs or hypoxic cytotoxins (recently reviewed in ref 24).
These compounds contain functional groups that are
susceptible to in vivo reduction under conditions of low oxygen
concentration. Although there are ﬁve chemical moieties that
have been demonstrated to undergo metabolism in hypoxia, the
most common approach employs nitroaromatic derivatives,
such as the 4-nitrobenzyl, 4-nitrofuryl, and 2-nitroimidazole
groups.24 The nitro group undergoes nitroreductase-mediated
one electron reduction to a radical anion in vivo, which is
rapidly oxidized by molecular oxygen under normoxic
conditions, forming superoxide and rendering this pathway
unproductive. Under hypoxic conditions, the radical anion is
not reoxidized but undergoes further reduction to form a
nitroso group, hydroxylamine, or an amine. While the nitro
group has no available lone pair and is mesomerically and
inductively electron-withdrawing, the nitroso group, the
hydroxylamine, and the amine groups have an available lone
pair and hence are mesomerically electron-donating. This
reversal in reactivity has been harnessed to activate compounds
selectively under hypoxic conditions. The majority of these
compounds are based on increasing the electrophilicity of
alkylating agents that then confer general toxicity in the hypoxic
region. A number of these agents have been described,
including tirapazamine (TPZ), AQ4N, PR-104A, CEN-209,
RH-1, and TH-302.25−28 TPZ has been tested in a number of
clinical trials including a recent large randomized multicenter
phase III trial combined with radiotherapy for head and neck
cancers. This trial reported no beneﬁt, although there were
major deﬁciencies in the treatment of a subset of patients that
Figure 1. Targeting Chk1/Aurora A inhibition to hypoxic cells. (a) Chk1 is phosphorylated and active in hypoxic conditions. RKO cells were
exposed to hypoxia (≤0.02% O2) for the times indicated, and Western blotting was carried out. (b) Increasing exposure time to Gö6976 (100 nM)
led to an accumulation of cells with >6 nuclear 53BP1 foci in WI38 cells. The inset shows an example of the 53BP1 foci observed. (c) RKO cells
were treated with the Aurora A kinase inhibitor MLN8237 at the concentrations indicated in either normoxic or hypoxic (≤0.02% O2) conditions for
16 h. A colony survival assay is shown.
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could be responsible for this.29,30 Subsequently, analogues of
TPZ have been described, one of which, CEN-209, is likely to
be tested clinically in the near future.31 More recently, TH-302
has undergone extensive preclinical testing and has been tested
in a phase II trial for advanced pancreatic cancer and a phase III
soft-tissue sarcoma trial.32 Several factors are critical to the
future success of bioreductive prodrugs, including the
challenges of delivering such agents to hypoxic tumor cells
and the need to identify biomarkers, which predict those
tumors most likely to respond.
The majority of the bioreductive prodrugs described to date
are designed to release a DNA damaging cytotoxin and
therefore, once activated, act similarly to conventional chemo-
therapeutic agents. This approach raises the possibility of
overlapping toxicities when these agents are combined with
standard therapies. An alternative application of a hypoxia-
activated group is to mask a drug, which acts as a protein ligand,
to prevent binding to its target. This would render the
compound inactive until the bioreductive group is removed
under hypoxic conditions. Given that this strategy potentially
allows targeting of promising cancer therapies to hypoxic
tumors, it is surprising that it has not been more widely
employed, although there are a few reports in the literature.
Zhang et al. applied this strategy to the synthesis of three
hypoxia-activated derivatives of 20(S)-camptothecin.33 They
demonstrated that a 4-nitrobenzyl derivative conferred some
selectivity for hypoxic cells over normal cells. Granchi et al.
described nitrobenzyl and nitrofuryl bioreductive prodrugs that
release an inhibitor of the lysyl oxidase (LOX) protein in
hypoxia.34 In this instance the approach was beneﬁcial as the
released compound, BAPN, is a relatively nonselective LOX
inhibitor with multiple biological interactions. Zhu et al.
synthesized 4-nitrobenzyl derivatives of O6-benzylguanine,
which is an inhibitor of the resistance protein O6-alkylguanine
alkyltransferase (AGT).35 It was demonstrated that the gem-
dimethyl-4-nitrobenzyl analogue was eﬀective in sensitizing
laromustine-resistant DU145 human prostate carcinoma cells
to laromustine under hypoxic conditions. Here, we describe
CH-01, which is a proof-of-concept compound that we propose
is activated as a Chk1 and Aurora kinase A inhibitor after the
hypoxia-promoted loss of the 4-nitrobenzyl group. Clonogenic
survival assays demonstrate that CH-01 (1) had little or no
eﬀect on cells in normal oxygen conditions; conversely, hypoxic
cells were extremely sensitive to CH-01. Of the tumor cell lines
Figure 2. The concept of the hypoxia-activated Chk1 inhibitor CH-01 and its synthesis. (a) Attachment of the 4-nitrobenzyl group to the terminal
hydroxyl group renders the Chk1 inhibitor 6 inactive. Under hypoxic conditions, the nitro group is reduced forming an electron-donating
substituent, which ejects the active Chk1 inhibitor 6. (b) Reagents and conditions: (a) malononitrile, Et2NH, dioxane, reﬂux, 16 h, 75%; (b) acetic
formic anhydride, 85 °C, 6 h; (c) neat, 220 °C, 30 min, 51% over two steps; (d) POCl3, 55 °C, 2 h, 81%; (e) Et3N, DMF, 80 °C, 6 h, 93%.
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tested, the sensitivity to CH-01 correlated with the baseline
levels of DNA damage/replication stress. Therefore this
strategy allows us to concentrate Chk1/Aurora kinase A
inhibition in hypoxic cells, targeting the most aggressive tumor
fraction, while protecting normal tissue.
■ RESULTS AND DISCUSSION
We have shown that depletion or inhibition of Chk1 sensitizes
cells to hypoxia/reoxygenation.22,36 The biological reasons
behind this observation include our ﬁnding that Chk1 has a role
to play in reoxygenation-induced replication restart, as well as
normal replication.23 In order to further validate Chk1 as a
molecular target in hypoxic conditions, we have considered its
autophosphorylation site serine 296 and the ATR-mediated
phosphorylations on serine residues 317 and 345 as well as the
total levels of Chk1. Chk1 was rapidly phosphorylated at all
tested residues (Figure 1a). To verify that the hypoxia-mediated
phosphorylation of Chk1 correlated with Chk1 activity, the
levels of the Chk1 target Tousled-like kinase 1 (TLK1) are also
shown.37 As described previously, the total levels of Chk1
decrease during increasing exposure to hypoxia.23 It is clear
caution is warranted when considering the inhibition of
essential genes such as Chk1. To demonstrate this point we
exposed nontransformed human fetal lung ﬁbroblasts (WI38)
to a well-characterized Chk1 inhibitor, Gö6976, in the absence
of additional stress. Increasing exposure to Gö6976 led to a
signiﬁcant accumulation of cells with more than six 53 binding
protein 1 (53BP1) foci indicating that prolonged exposure to a
Chk1 inhibitor leads to accumulation of DNA damage, which
could in turn aﬀect genome stability (Figure 1b). In order to
target Chk1 kinase inhibition to the hypoxic regions of tumors,
we synthesized a bioreductive Chk1 inhibitor, CH-01 (1). CH-
01 is based on the Chk1 inhibitor 6 (Figure 2a) reported by
Foloppe et al.38 During the course of this work, compound 6
was also shown to inhibit Aurora kinase A.39 Inhibitors of
Aurora kinases have been tested clinically and show some
promise; however, these agents have not been tested speciﬁcally
in hypoxic conditions.40 In order to investigate the potential
beneﬁt of Aurora A inhibition in hypoxic cells, we incubated
RKO cells with the known selective Aurora A inhibitor
MLN8237 in both normoxic and hypoxic conditions. The
colony survival assay shown demonstrates that cells in both
normoxia and hypoxia are sensitive to inhibition of Aurora A
(Figure 1c).
Synthesis of a Bioreductive Chk1/Aurora A Inhibitor.
Compound 6 was selected for its chemical simplicity and the
well-deﬁned Chk1 structure−activity relationships (SAR)
reported around this scaﬀold. Compound 6 inhibits Chk1
kinase in an ATP competitive manner with a reported IC50
value of 20.9 μM, and the SAR showed that addition of a large
substituent in place of the hydroxyl group resulted in a
signiﬁcant reduction in Chk1 aﬃnity. Examination of an X-ray
crystal structure of 6 bound to the ATP binding site of Chk1
reveals that the hydroxyl group binds oriented into a pocket,
which is too small to accommodate a substituent such as the 4-
nitrobenzyl group. This observation was corroborated by
docking studies (see Supplementary Figure S1). Consequently
we designed compound 1, which we predicted to be inactive as
a Chk1 inhibitor until the 4-nitrobenzyl group is removed in
hypoxia (Figure 2a). Structure−activity studies have shown that
compound 6 inhibits Aurora kinase A with an IC50 value of 309
nM.39 In addition, these studies showed that larger groups,
including 4-aminophenyl derivatives, were tolerated in place of
the hydroxyl group. To predict whether addition of a 4-
nitrobenzyl group would reduce the compound’s aﬃnity for
Aurora kinase A, we undertook docking studies. These studies
suggested that although both compound 1 and compound 5
would bind to Aurora kinase A with a reduced aﬃnity
compared to that of compound 6, they could potentially still
be accommodated in the ATP-binding site (see Supplementary
Figure S2A and B). Compound 1 was synthesized using
conditions similar to those reported by Foloppe (Figure 2b).
Benzoin (7) was condensed with malononitrile to give 2-
aminofuran 8. Reaction with acetic formic anhydride aﬀorded
the formamide 9, which cyclized to give 10 upon heating.
Treatment of 10 with phosphorus oxychloride furnished the
chloride 11, which underwent facile reaction with O-(4-
nitrobenyl)ethanolamine (12) to give the ﬁnal product (1).
Analysis of compound 1 in a radioactive (33P-ATP) ﬁlter-
binding assay revealed no activity against either Chk1 or Aurora
kinase A at concentrations up to 100 μM (Supplementary
Figure 3. CH-01 is reduced and fragments in hypoxic conditions. CH-01 was subjected to diﬀerent reduction conditions, and the resulting
metabolites were analyzed by HPLC. A combination of photodiode array spectrophotometer, mass spectrometer, and ﬂuorescence
spectrophotometer (λex 320 nm, λem 380 nm) was used to detect and characterize the metabolites. (a) CH-01 was subjected to zinc reduction
for 1 h, and this solution was injected into potassium phosphate buﬀer pH 7.4. Incubation at 37 °C and analysis of the supernatant reveal loss of the
amine 5 and formation of the active inhibitor 6. (b) Bactosomal human NADPH-CYP reductase reduces CH-01 (1) to the amine 5 under hypoxic
conditions (≤0.02% O2). Over 24 h amine 5 accumulates and fragments to release the active inhibitor 6.
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Figure S3). Conversely, compound 6 showed IC50 values of
1.75 and 0.81 μM against Chk1 and Aurora kinase A,
respectively.
Mechanism of CH-01 Action. To determine whether 1
fragmented under reducing conditions as predicted, we carried
out two reductions in progressively more biologically relevant
conditions. Shigenaga et al. have previously employed zinc in
aqueous ammonium chloride to reduce a 4-nitrobenzyl group
to a 4-aminobenzyl group and hence demonstrate hypoxic
activation of a peptide.41 Using similar conditions of zinc and
ammonium chloride in N,N-dimethylformamide (DMF), we
demonstrated that 1 was reduced to give the nitroso compound
4 (conﬁrmed by mass spectrometry) and the amine 5 after a
period of 60 min (Supplementary Figure S4a). Upon exposure
to aqueous conditions (potassium phosphate buﬀer, pH 7.4),
HPLC analysis indicated that compounds 4 and 5 fragmented
to give the active kinase inhibitor 6 (Figure 3a and
Supplementary Figure S4b). Encouraged that we had proved
reduction of 1 could induce fragmentation in buﬀer, we treated
1 with bactosomal human NADPH-CYP reductase in
potassium phosphate buﬀer with the exclusion of oxygen.
Under these conditions reduction of the 4-nitrobenzyl group of
1 to the 4-aminobenzyl derivative 5 was observed and
fragmentation to the active inhibitor 6 occurred. When this
experiment was repeated in the presence of oxygen, no
reduction or production of compound 6 was observed (Figure
3b and data not shown). These results indicate that the
nitrobenzyl group is reduced under purely chemical conditions
and by reductase enzymes in hypoxic conditions. The reduced
products fragment to give the active kinase inhibitor 6 in a
manner consistent with the proposed in vitro mode of
activation for compound 1.
In Hypoxic Conditions CH-01 Leads to Loss of Cell
Viability. Loss or inhibition of Chk1 has been shown to induce
DNA damage due to impaired replisome stability and DNA
repair.42 Therefore, we investigated whether CH-01 (1)
induced DNA damage in normoxia, hypoxia, and after
reoxygenation. Initially, we carried out Western blotting for
γH2AX and determined that the presence of 1 in hypoxic
conditions led to an increase in the hypoxia-induced γH2AX
signal (Figure 4a). As the robust induction of γH2AX by
hypoxia alone makes this signal diﬃcult to quantify we used the
formation of 53BP1 foci as an alternative measure of DNA
damage. As shown previously, hypoxia alone did not induce an
accumulation of 53BP1 foci, although subsequent reoxygena-
tion did cause DNA damage.21 In contrast, exposure to 1 in
hypoxia alone led to the accumulation of 53BP1 foci in over
50% of the cells (Figure 4b). These data indicate that CH-01
leads to the accumulation of DNA damage only in hypoxic
conditions.
To conﬁrm that 6 inhibits Aurora A/B, we treated RKO cells
with CH-01 (1) in hypoxic conditions and then carried out
Western blotting for histone-3 phosphorylated at serine 10,
which is a characterized target of Aurora A/B.43 Treatment of
RKO cells in normoxia with MLN8237 demonstrated that
phosphorylation of pH3 at ser10 can be inhibited through
Aurora A inhibition. In contrast, 1 has no eﬀect on this signal in
normoxic conditions, indicating that this compound does not
inhibit Aurora A/B. In response to hypoxia the pH3 ser10
signal decreased, and this decrease was exacerbated in the
presence of 1. After subsequent reoxygenation a clear and
Figure 4. CH-01 induces DNA damage and is toxic in hypoxic conditions. (a) RKO cells were exposed to normoxia or hypoxia (≤0.02% O2) for 6 h
in the presence or absence of 25 μM CH-01 (1). Western blots for γH2AX and actin are shown. (b) RKO cells were exposed to normoxia or hypoxia
(≤0.02% O2) for 6 h and hypoxia followed by 18 h of reoxygenation ± 1 (25 μM). The graph shows the percentage of cells with >6 nuclear 53BP1
foci. Signiﬁcance values: * p < 0.05; **p < 0.0001. (c) RKO cells were exposed to hypoxia for the time periods indicated with either 1 (25 μM),
MLN8237 (500 nM) or, as a control, DMSO. The levels of phosphorylated histone 3 (pH3 Ser10) were determined by Western blotting. Histone 3
(H3) is shown as loading control. (d) Clonogenic assays were carried out on RKO cells exposed to the oxygen tensions indicated for 24 h in the
presence of 25 μM 1 or DMSO.
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signiﬁcant reduction of pH3 Ser10 was observed when RKO
cells were incubated with 1 during hypoxia prior to
reoxygenation (Figure 4c). These data suggest that 1 is
reduced and fragmented to give 6, which inhibits both Chk1
and Aurora A/B. This dual inhibition is beneﬁcial as both Chk1
and Aurora A are involved in cell cycle progression and are
therapeutic targets. Next, we exposed RKO cells to 1 and
incubated the cells in oxygen concentrations ranging from 20%
to ≤0.02% O2 (Figure 4d). A colony survival assay was carried
out at each of the oxygen tensions indicated and demonstrates a
signiﬁcant oxygen-dependent loss of viability. Most impor-
tantly, at oxygen levels associated with normal tissues (3% O2
and above) there was little or no eﬀect on cell viability.
It was important to determine that the biological eﬀects
observed were due to the release of 6 and not the bioreductive
cage. Cells were exposed to the nonbioreductive inhibitor 6,
compound 13, which releases EtOH under hypoxic conditions,
and CH-01 (1, Figure 5a,b). As expected, RKO cells were
sensitive to Chk1 inhibitor 6 ,and this sensitivity was increased
in hypoxic conditions as previously reported. In contrast, 1 had
no signiﬁcant eﬀect on the normoxic cells but signiﬁcantly
increased the sensitivity to hypoxia/reoxygenation. Importantly,
compound 13 did not decrease cell viability, suggesting that the
release of the reduced nitrobenzyl group side product alone is
not cytotoxic.
Up to this point our studies had been restricted to the RKO
cell line. However, we proposed that diﬀerent cells lines would
show varying degrees of sensitivity to 1. To investigate this
hypothesis further we used three lung cancer cell lines (A549,
H1299, and H1975) to determine the eﬀect of 1 in normoxia
and hypoxia. Recent, reports suggest that the baseline levels of
DNA damage and/or replication stress contribute to the
relative sensitivity to Chk1 inhibitors. We proposed that this
might also be the case for inhibitors of alternative kinases
involved in the cell cycle and so might predict sensitivity to
inhibition of Chk1 and Aurora A by 1. Therefore, before testing
the eﬀect of 1 on cell viability in hypoxic conditions, we
measured the basal levels of DNA damage and replication stress
in these 3 cell lines. This measurement was achieved by staining
for both 53BP1 and γH2AX, which are markers of DNA
damage and/or replication stress (Figure 6a,b). In each cell line
a signiﬁcant proportion of the cells were found to be positive
for these markers, although both the H1299 and H1975 cell
line had higher levels of 53BP1/γH2AX positive cells than the
A549s. Interestingly, large nuclear bodies were seen in the
H1299 cell line, which were reminiscent of the recently
described Oct-1, PTF, transcription (OPT) domains.44 These
data suggest that the A549 cell line should show the least
sensitivity to 1 in hypoxic conditions. To test this hypothesis,
the cell lines were exposed to 1 for 24 h in either normoxia or
hypoxia (≤0.02% O2). As predicted all three-cell lines were
sensitive to 1 in hypoxic conditions, and of the three the A549
cells were the least sensitive. However, despite the relatively
similar levels of DNA damage seen in the H1299 and H1975
cell lines, the latter were signiﬁcantly more sensitive to 1. Our
data demonstrate that all four of the cell lines tested show
increased sensitivity to 1 in hypoxia and that the degree of
sensitivity can, in part, be determined by the basal levels of
DNA damage/replication stress. In order to use an agent such
as 1 most eﬀectively, the degree of tumor hypoxia would have
to be determined prior to treatment.45−47 It is clear that
nonhypoxic tumors would not respond and the more hypoxic
the greater the predicted response (Figure 4d). However, the
sensitivity to 1 is also determined by additional factors
including the levels of DNA damage/replication arrest. We
propose that 1 and derivatives would be eﬀective against
tumors with high levels of hypoxia or oncogene-mediated
replication stress. In mildly hypoxic tumors, which are less
susceptible to Chk1 inhibition due to low levels of replication
stress for example, we predict that combining 1 with standard
therapies would be eﬀective.
Conclusions. We conﬁrm earlier ﬁndings that inhibition of
Chk1 is a valid approach to target hypoxic cancer cells. In
addition, we have demonstrated that hypoxic cells show similar
levels of sensitivity to inhibition of the Aurora A kinase as cells
in normoxia. Here, we describe a bioreductive Chk1/Aurora A
inhibitor, CH-01 (1), which selectively inhibits Chk1/Aurora A
in hypoxic conditions and leads to signiﬁcant loss of viability in
the cancer cell lines tested. Although a proof-of-concept
compound, the selective activity demonstrated by 1 suggests
the potential for the bioreductive release of targeted therapies
and demonstrates this approach as a promising strategy for the
targeted application of cancer chemotherapeutics.
■ METHODS
Cell Lines. RKO (colorectal), A549, H1299, and H1975 (lung)
cancer cell lines were cultured in DMEM medium containing 10%
FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL). WI38
nontransformed human fetal lung ﬁbroblasts were grown in DMEM
medium with 15% FBS. All cell lines were originally obtained from the
ATCC and routinely mycoplasma tested and found to be negative.
With the exception of colony survival experiments all others were
carried out with cells at 75% conﬂuence.
Chemical Synthesis. Details of the chemical synthesis and
analytical data for the compounds described are available in the
Supporting Information. Gö6976 was obtained from Sigma-Aldrich
and MLN8237 from Selleckchem.
Hypoxia Treatment. Hypoxia treatments were carried out in a
Bactron II (Shell laboratories), In vivo 400 (Ruskinn), or Heracell
mixed gas incubator (Fisher Scientiﬁc) depending on the level of
hypoxia required.
Clonogenic Assay. Colonies (>50 cells) were left to form for 10
days and visualized with methylene blue stain (70% methanol in PBS,
1% methylene blue (Fisher BioReagents)).
Western Blotting. Cells were lysed in UTB (9 M urea, 75 mM
Tris-HCl pH 7.5 and 0.15 M β-mercaptoethanol) and sonicated
brieﬂy. Antibodies used were Chk1-S296, Chk1-S317, Chk1-S345,
Figure 5. The biological activity of CH-01 is not associated with the
bioreductive group. (a) Clonogenic assays were carried out using RKO
cells exposed to DMSO, 25 μM inhibitor 6, 25 μM CH-EtOH 13 or
25 μM CH-01 1 for 24 h in either normoxia or hypoxia (≤0.02% O2).
(b) The structure of compound 13, which ejects EtOH under hypoxic
conditions.
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HIF1α (BD Biosciences), Chk1, γH2AX (Upstate-Millipore), H3-S10,
TLK-S695 (Cell Signaling), and GAPDH (Fitzgerald Industries). The
Odyssey infrared system was used for imaging (LI-COR Biosciences).
Zinc Reduction of 1. To a solution of 1 (1 mg, 0.0021 mmol) in
DMF (2 mL) were added aqueous ammonium chloride (20 μL, 10%
w/v) and zinc powder (5 mg, 0.0765 mmol, 36 equiv). The resulting
mixture was stirred at ambient temperature for 16 h. Aliquots (200
μL) were taken at designated times (where T = 0 refers to before the
addition of zinc powder), and the mixture was analyzed by HPLC.
Buﬀer Treatment of 5. For every time point of interest, 5 μL of
the T = 1 h aliquot from the zinc reduction was injected into 95 μL of
potassium phosphate buﬀer solution (pH 7.4), and the resulting
suspensions were incubated at 37 °C. At designated times the
suspensions were centrifuged. The supernatant was collected, and the
precipitates were dissolved in acetonitrile. Both fractions were analyzed
by HPLC.
Reductase Assay. Bactosomal human NADPH-CYP reductase
(Cypex, 12.7 mg/mL, 13900 nmol/min/mL) was used in combination
with an NADPH-regenerating system (BD Biosciences), and the assay
was carried out according to the manufacturer’s protocol (BD
Biosciences application note 467) at a CH-01 concentration of 250
nM. Vials were deoxygenated by bubbling nitrogen prior to P540
addition and then transferred into a Bactron II (Shell laboratories).
Samples were taken at diﬀerent time points and analyzed by HPLC.
Immunoﬂuorescence. Staining for 53BP1 (Novus Biologicals)
and γH2AX foci was carried out as previously described.21 Due to the
presence of 1−2 53BP1 foci in the nuclei of unstressed cells, induction
of DNA damage was quantiﬁed by counting cells with more than 6
foci. Cells were visualized using a Nikon 90i microscope.
HPLC Analysis. HPLC (Waters 2695 system) comprised an RPB
column (100 mm × 3.2 mm, 35 °C). Separation was achieved at a ﬂow
rate of 0.5 mL/min with a gradient of 60−95% acetonitrile in 10 mM
formic acid over 6 min. Detection used a photodiode array
spectrophotometer (Waters 2996), a mass spectrometer (Waters
Micromass ZQ mass spectrometer), and a ﬂuorescence spectropho-
tometer (Waters 474) with λex 320 nm, λem 380 nm. Injections of 10
μL were made.
Statistical Analysis. Statistical signiﬁcance of diﬀerences between
means of at least n = 3 experiments was determined using Student’s t
test (P-values indicated accordingly in ﬁgure legend or main text).
Error bars represent ± SEM.
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or hypoxia (≤0.02% O2), and colony survival assays were carried out.
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